Focused Ultrasound Systems Market – By Product, By Application, By End Use – Global Forecast 2025 – 2034

Focused Ultrasound Systems Market Size

The global focused ultrasound systems market size was valued at USD 264.4 million in 2024 and is expected to reach USD 642.4 million in 2034, growing at a CAGR of 9.4% from 2025 to 2034. Focused ultrasound systems are non-invasive medical technologies that use concentrated ultrasound energy to precisely target tissues within the body. These systems can treat conditions by generating thermal, mechanical, or biological effects without the need for surgery.
 

The prevalence of chronic diseases has been growing globally, which is a factor primarily impacting the growth of market positively. For instance, according to the World Health Organization (WHO), around 74% of deaths occurring worldwide are due to non-communicable diseases (NCDs), along with 17 million premature deaths every year.
 

Moreover by 2050, if the current trends were to continue, chronic conditions such as cancer, diabetes, cardiovascular diseases, and respiratory diseases would account for 86% of the 90 million annual deaths, which is 90% of increase in absolute numbers since 2019. Such statistics show the need for modalities like HIFU and LIFU, which give precise tumor targeting and ability through real-time imaging integration with MRI or ultrasound.
 

Moreover, the patients prefer non-invasive and minimally invasive procedures, which is also aiding in market growth of focused ultrasound systems. For both patients and healthcare practitioners, these are better options than surgery or radiation because of lower complication levels, quicker recovery periods, and shorter hospital stays. Focused ultrasound is used in prostate cancer, uterine fibroids, essential tremor, and skin tightening without the need for scarring or radiation, making it an outpatient-friendly procedure. For instance, according to Statista, 831,583 skin tightening procedures were performed globally in 2023. Thus, owing to patients’ benefits in the procedures, the market is expected to bolster in the forecast period.
 

Focused Ultrasound Systems Market Trends

• Focused ultrasound systems are increasingly used for treating essential tremor, Parkinson’s disease, and neuropathic pain. Increasing regulatory approvals are supporting market expansion. For instance, Insightec’s Exablate Neuro system has received regulatory approvals in multiple countries for treating medication-refractory essential tremor, contributing to the growing adoption of non-invasive neurosurgery.
   
• There is an increase in patients in the outpatient settings. Outpatient HIFU therapies are now common in hospitals and specialized clinics, which minimizes the length of stay and costs associated with care. This trend will also be noticeably spurred by the growth of the ambulatory surgical centers (ASC) market, which is expected to reach USD 93.8 billion by 2032.
   
• Complementing HIFU, LIFU is also emerging as a possible modality as an adjunct to HIFU, especially in neuromodulation and the management of uterine fibroids, as it is harmless and can modulate tissue without inducing thermal damage.
   
• Further, real-time imaging, AI components, LIFU and HIFU have made treatment more accurate. There are improvements in ultrasound beam focusing as well as in the personalized treatments, further fostering the growth of this market.
   

Focused Ultrasound Systems Market Analysis

Based on product, the market is segmented into high intensity focused ultrasound (HIFU) systems and low intensity focused ultrasound (LIFU) systems. The high intensity focused ultrasound (HIFU) systems segment dominated the market with the largest revenue of USD 260.8 million in 2024.
 

• HIFU technology has emerged as a leading driver in the product category as a result of growing demand for non-surgical treatment modalities for cosmetic and therapeutic uses.
   
• A prominent reason is the growing demand for HIFU in oncology, especially for the treatment of prostate cancer and uterine fibroids, wherein it offers scarring-free and radiation-free therapy. For example, as per the International Agency for Research on Cancer, 2025, the global incidence of prostate cancer, which has seen more than 1.4 million new cases, has driven the clinical uptake of HIFU as a safer procedure with fewer complications.
   
• Similarly, as per the study by National Institutes of Health (NIH), nearly 70–80% of women are estimated to develop UFs throughout their lifetime. The rising prevalence of uterine fibroids in nearly 70% of women aged over 50 years has led to greater use of HIFU in uterine-sparing procedures. Hence, HIFU is expected to maintain its market dominance throughout the forecast period.
   

Based on application, the focused ultrasound systems market is segmented into clinical applications and research applications. The clinical applications segment is further sub segmented in to uterine fibroids, prostate cancer, essential tremor, dermatology, breast cancer, glaucoma, backpain, and other applications. Clinical applications segment accounted for the largest revenue share of 98.2% in 2024.
 

• The market is dominated largely by the growing need for non-surgical and targeted therapy modalities for a variety of medical conditions. Amongst them, uterine fibroids are a significant contributor in this segment due to the growing demand for non-surgical treatments which enable fertility preservation and reduce recovery time.
   
• Further, the rising prevalence of neurological conditions such as essential tremors is also contributing to demand, as focused ultrasound provides safe non-surgical treatment compared to traditional surgery. In dermatology, the use of focused ultrasound for skin tightening and rejuvenation, fueled by growth in aesthetic procedures, is on the surge.
   
• Moreover, the treatment of breast cancer is complemented by the modality's ability for tumor ablation with limited destruction, especially in the conservation of the breast tissue. The possibility of focused ultrasound as treatment for glaucoma and chronic back pain further increases its clinical utility.
   
• Together, these subsegments drove market growth, supported by ongoing innovation, increasing patient awareness, and increased healthcare investment in less invasive treatment with higher efficacy, safety, and faster recovery.
   

Based on end use, the focused ultrasound systems market is segmented into hospitals, imaging centers, academic and research institutes, and other end users. Hospitals segment accounted for the largest revenue share of 62.2% in 2024.
 

• The rising number of hospitals globally, driven by population growth, urbanization, and enhanced medical technology, plays a significant role in fueling the escalating needs for both high intensity focused ultrasound (HIFU) and low intensity focused ultrasound (LIFU) systems. As new medical centers open for the first time or are rebuilt, demand for non-invasive, state-of-the-art therapeutic technology such as focused ultrasound systems increases to meet diverse patient care requirements in oncology, gynecology, neurology, and pain management. Both HIFU and LIFU offer precision, faster recovery, and enhanced results, in line with the trend towards patient-friendly, incision-free treatment regimens.
   
• Moreover, government and private investments are propelling hospital infrastructure growth, thereby supporting market growth. Sufficient investments are being undertaken to enhance hospital capabilities, acquire next-generation non-invasive therapeutic systems, and enhance service offerings.
   
• Improvements in technology, such as real-time imaging guidance, higher energy delivery, and sophisticated treatment monitoring, are boosting the clinical value of these systems and broadening their hospital-based applications.
   

North America held a significant share of the global focused ultrasound systems market in 2024, accounting for 39.2% of the total market. The region has advanced healthcare infrastructure and rate of adoption of innovative medical technologies is also high. Further, there is an increasing prevalence of chronic diseases in the U.S. and Canada which includes prostate cancer and uterine fibroids as well. 
 

The U.S. market was valued at USD 76.5 million and USD 81.2 billion in 2021 and 2022, respectively. The market size reached USD 93.8 million in 2024, growing from USD 87 million in 2023.
 

• The country faces a high burden of prostate cancer. According to the U.S. Centers for Disease Control and prevention, in 2021, 236,659 new prostate cancers were reported and in 2022, 33,363 males died from prostate cancer.
   
• Similarly, the Global Cancer Observatory reported that in 2022, approximately 89.1% of cancer cases in North America occurred in the U.S., highlighting the country’s burden of oncological diseases. As a result, the expansion of non-invasive surgical suites is driving the adoption of both HIFU and LIFU systems globally.
   
• Moreover, U.S. has a strong healthcare infrastructure, which benefits in rising adoption of non-invasive therapies, strong regulatory approvals, and increasing investment in healthcare innovation.
   
• Thus, the country foresees a strong boost in the revenue generated from HIFU in upcoming years.
   

Europe focused ultrasound systems market accounted for USD 72.2 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe plays a pivotal role in advancing the global market, driven by its strategic adoption of both HIFU and LIFU technologies. The market in Europe is expanding considering the surge in prevalence of chronic diseases, that include cancer and uterine fibroids, coupled with advancements in non-invasive treatment technologies. According to the data from Statista, in 2022, the average incidence of breast cancer across EU-27 was 147.6 per 100,00 population.
   
• Additionally, Germany, France, and the UK are at the forefront of adopting HIFU and LIFU technologies. These countries also have support for favorable healthcare policies and investments in research and development. Public-private partnerships as well as government initiatives that improve healthcare infrastructure are further helping the market's growth in the region.
   

The UK focused ultrasound systems market is projected to experience steady growth between 2025 and 2034.
 

• In the UK, initiatives designed to enhance the reach of HIFU are being put into practice by government as well as non-profit organizations.
   
• For instance, Graham Fulford Charitable Trust (GFCT) is executing a strategy to expand the availability of the HIFU machine in NHS hospitals by offering them on a rental basis. One fully sponsored facility already being installed at Northampton General Hospital and few units are being used in King’s Lynn and Bath.
   
• Further, units are planned for installation in Leeds, Fife, and Plymouth/Truro. This will improve access to HIFU treatment for the residents of the Midlands, East Anglia, and the Southwestern parts of England.
   
• Additionally, the UK Focused Ultrasound Foundation, in collaboration with Race Against Dementia, has launched the country’s first clinical trial using low-intensity focused ultrasound (LIFU) to treat cognitive decline in Lewy body dementia patients. Conducted by researchers at the University of Oxford and UCL, this initiative reflects the growing momentum behind focused ultrasound systems in addressing neurological conditions and expanding non-invasive treatment access nationwide.
   

The Asia Pacific region is projected to be valued at USD 68.5 million in 2025 and is expected to reach USD 164.7 million by 2034.
 

• The Asia Pacific HIFU and LIFU market is projected to experience steady expansion, which is due to the surge in demand for non-invasive therapeutic alternatives and strong government initiatives made to enhance the healthcare infrastructure and expanding access to advanced medical technologies. For instance, India’s total healthcare expenditure was USD 9.51 billion in 2023–24 which grew till USD 10.8 billion in 2024–25.
   
• Furthermore, a significant piece of this increase is seen in the allocated budget for the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PMABHIM), that also observed an increase to USD 493 million.
   
• These investments underscore a regional commitment to bolstering healthcare capacity critical for the adoption and maintenance of advanced focused ultrasound systems.
   

Japan focused ultrasound systems market is poised to witness lucrative growth between 2025 – 2034.
 

• The adoption of focused ultrasound technology in Japan is continually growing as it is already being used in prostate enlargement, Parkinson’s, and essential tremor conditions. HIFU research and clinical applications are now being directed towards pancreatic cancer treatment, which is one of the most difficult and deadly cancers.
   
• It is estimated that approximately 70% of all pancreatic cancer cases in Japan are diagnosed at an advanced stage where surgery becomes impossible. Thus, the 3-year survival rate is observed only in 3.2% of patients. Even after surgery, nearly 80% of patients experience recurrence.
   
• Unlike conventional radiation treatment, which requires daily sessions spanning over six weeks, HIFU reduces the number of sessions required to achieve the same results. This increases patient outcomes and acceptance of the technology in Japan’s oncology landscape.
   
• Therefore, HIFU technology in Japan is expected to grow significantly in coming years. The country is also witnessing early-stage clinical research into LIFU applications, particularly in neurodegenerative diseases, aligning with Japan’s aging population and advanced healthcare infrastructure.
   

Brazil is experiencing significant growth in focused ultrasound systems market, driven by its expanding adoption of chronic disease management.
 

• In Brazil, breast cancer was the most frequently diagnosed cancer among women in 2020. According to the Global Cancer Observatory, an estimated 66,280 new cases were reported throughout the year, representing 29.7% of all cancer types and an incidence rate of 43.7 per 100,000 women. Therefore, there is a growing need for solutions non-invasive solutions to support traditional oncology treatments.
   
• Additionally, Brazil faces a challenge of aging population, which further fuels demand for HIFU in the country. According to the Brazilian Institute of Geography and Statistics, number of individuals aged 65 and older reached 22.17 million in 2022, accounting for 10.9% of the total population in the country. This was a 57.4% increase since the year 2010. Conditions such as prostate cancer and uterine fibroids are observed to be more prevalent in geriatric population. This trend is expected to boost the adoption of non-invasive, outpatient-friendly therapies like HIFU and LIFU.
   

The focused ultrasound systems market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi government healthcare spending under the Saudi Vision 2030 initiative has increased access to sophisticated medical technologies. In 2023, the Saudi government set aside more than USD 1.5 billion towards the expansion for medical technology which is expected to boost the use of HIFU and LIFU as well. HIFU is now being adopted in cancer treatment protocols at major hospitals such as King Faisal Specialist Hospital & Research Centre.
   
• Moreover, Saudi Arabia's elderly population is rising at a much faster pace than any other segment. It is estimated that the population aged 60 years and above will grow from 2 million (5.9 percent of the total population) in 2020 to 10.5 million by 2050. This population shift will lead to greater demand for HIFU and LIFU treatment for prostate cancer as well as other applications in the foreseeable future.
   

Focused Ultrasound Systems Market Share

The top 5 players involved in the competition in the market are Iljin Holdings Co., Ltd. (ALPINION MEDICAL SYSTEMS), Chongqing Haifu Medical Technology Co., Ltd., Profound Medical Corp, EDAP TMS S.A., and Insightec Ltd, which focus on technological innovation, clinical trials, and regulatory processes for focused ultrasound applications across oncology, neurology, and urology.
 

These companies collectively account for approximately 53% of the market revenue share. These big players are also focusing on improvement of adoption as well as reimbursement coverage, by making collaborations and strategic partnerships. Emerging entrants are developing next-generation focused ultrasound systems with enhanced imaging precision and guidance capabilities, including portable and ultrasound-integrated systems aimed at increasing accessibility and treatment accuracy.
 

Focused Ultrasound Systems Market Companies

Some of the eminent market participants operating in the focused ultrasound systems industry include:

• Brainsonix
• Chongqing Haifu Medical Technology
• EDAP TMS
• EpiSonic
• FUSMobile
• Insightec
• ILJIN Holdings
• Lynton Lasers
• Profound Medical
• Sonablate
• Theraclion
• Ultraiser
• Verasonics
   
• Theraclion specializes in robotic HIFU platforms for non-invasive treatment of thyroid nodules and varicose veins, to improve treatment efficiency and precision.
   
• EDAP TMS has expertise in ultrasound-based therapies ensures effective tumor ablation with minimal side effects. The company offers a comprehensive HIFU portfolio, including its flagship Focal One, which provides precise and non-invasive treatment for localized prostate cancer.
   

Focused Ultrasound Systems Industry News:

• In August 2024, FUSMobile’s Neurolyser XR received Health Canada approval for treating chronic low back pain from facet arthritis, enabling an anesthesia-free ultrasound therapy that is non-invasive in Canada.
   
• In January 2024, Insightec, one of the major players in the focused ultrasound technology, has been issued a positive recommendation from the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) with regards to the reimbursement for the use of MR-guided Focused Ultrasound (MRgFUS) treatment for essential tremor (ET). This was a major advancement in enabling the use of this non-invasive treatment within the Netherlands. This recommendation was published in December 2023, stating that for patients that suffer from moderate to severe medication resistant essential tremor and do not qualify for deep brain stimulation, MRgFUS or high intensity focused ultrasound (HIFU) therapy is a viable treatment option.
   
• In May 2021, Chongqing Haifu Medical Technology expanded its global footprint by deploying high-intensity focused ultrasound (HIFU) systems in Mexico, introducing non-invasive treatment alternatives for solid tumors such as those affecting the pancreas, bone, breast, uterus, and liver. This initiative marked a significant step toward enhancing cancer care accessibility and outcomes in the region.
   

The focused ultrasound systems market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• High intensity focused ultrasound (HIFU) systems
• Low intensity focused ultrasound (LIFU) systems

Market, By Application

• Clinical applications
• Uterine fibroids
• Prostate cancer
• Essential tremor
• Dermatology
• Breast cancer
• Glaucoma
• Backpain
• Other applications

• Research applications

Market, By End Use

• Hospitals
• Imaging centers
• Academic and research institutes
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE